0001213900-26-027725
SEC filingOnconetix, Inc. (ONCO) reported FY 2025 revenue of $815K, down 67.7% from $2.5M in 2024, primarily due to completion of a non-recurring development services contract with Immunovia, partially offset by $0.6M license revenue from a new agreement. Gross profit was $633K (77.6% margin), improved from $1.1M (41.8% margin) due to lower cost of revenue tied to services. Net loss narrowed to -$14.0M from -$58.7M, driven by $25.4M lower impairments (goodwill $11.5M vs $32.3M; no intangibles/ENTADFI impairments vs $13.8M/$3.5M prior year) and $7.1M net other income from warrant/derivative fair value gains. Operating loss improved 68.4% to -$17.9M. Cash increased to $5.2M from prior periods via $14.5M financing (Series D/E PIPE $15.5M net), offset by $9.7M operating use. Balance sheet shows $24.9M total assets, $15.8M equity, but $3.1M working capital deficit and going concern doubt. Focus remains Proclarix commercialization amid capital needs.
Onconetix reported FY 2025 revenue of $815K, a 67.7% decline from $2.5M in 2024, driven by absence of $2.3M development services from completed Immunovia contract, offset by $0.6M new license revenue and stable $0.2M product sales from Proclarix. Gross profit fell 40.0% to $633K (77.6% margin vs 41.8% prior), reflecting lower service-related costs. Operating expenses dropped 67.9% to $18.5M, primarily from $25.4M reduced impairments ($11.5M goodwill vs $46.1M total prior). Operating loss improved 68.4% to -$17.9M. Net loss narrowed 76.1% to -$14.0M, aided by $3.8M other income from warrant/derivative gains. Cash rose to $5.2M via Series D/E PIPE financings, despite $9.7M operating outflow. Going concern doubt persists with $3.1M working capital deficit.
Revenue totaled $815K, all from Proteomedix: $0.2M product sales (stable YoY), $0.6M other (new Immunovia license), no development services vs $2.3M prior. Proclarix sales steady at early commercialization stage in Europe (CE-marked, non-reimbursed). No U.S. revenue yet pending LabCorp validation. YoY decline reflects one-time service completion; management expects Proclarix growth in 2026.
Gross margin expanded to 77.6% from 41.8%, as cost of revenue fell 87.6% to $182K (no service amortization). SG&A declined 37.3% to $7.0M (headcount cuts, pension settlement). No R&D expense vs $0.2M prior. Impairments limited to $11.5M goodwill. Operating margin -2194% vs prior extremes. Net margin improved via non-operating gains/losses volatility.
Operating cash use $9.7M (net loss offset by $39.5M non-cash). Financing provided $14.5M (Series D $9.3M, Series E $6.2M, ELOC $6.4M), offset by $7.1M debt paydown. Balance sheet: $24.9M assets ($6.1M current, $18.5M goodwill), $9.2M liabilities ($9.1M current, incl. $9.3M notes, $7.0M derivatives), $15.8M equity. Liquidity strained; $5.2M cash, working capital deficit $3.1M.
Management highlights Proclarix commercialization focus post-ENTADFI abandonment. Expects 2026 revenue growth from European sales, U.S. LabCorp validation study. Requires additional capital for operations; no committed sources beyond ELOC. Going concern doubt noted; plans include equity/debt raises. Realbotix share exchange pending (Feb 2026 agreement), subject to $12.5M+ net cash, ELOC commitment. Nasdaq compliance regained July 2025 under monitor through 2026.